Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Safety of Etravirine in HIV-1
NCT00128830Phase 2Completed
- Sponsor
- Tibotec
- Start
- Jun 2005
- Primary completion
- Aug 2008
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of etravirine in human immunodeficiency virus type 1 infection (HIV-1), sponsored by Tibotec. Primary endpoint: Number of Participants With Adverse Events at 3 years. Started Jun 2005; status: completed.
02
Drugs
etravirine
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT00128830.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00128830.